These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18158039)

  • 41. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
    Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
    Xu DD; Sun SD; Wang F; Sun L; Stackhouse D; Polascik T; Albala DM; Moul JW; Caire A; Robertson CN
    Urology; 2009 Sep; 74(3):654-8. PubMed ID: 19628263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.
    Ward JF; Nakanishi H; Pisters L; Babaian RJ; Troncoso P
    BJU Int; 2009 Aug; 104(4):490-7. PubMed ID: 19220260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of quality of life after radical treatment for prostate cancer.
    Gacci M; Lapini A; Serni S; Livi L; Paiar F; Detti B; Simontacchi G; Vittori G; Giubilei G; Mariani M; Palli D; Carini M
    Urol Int; 2008; 80(3):231-6. PubMed ID: 18480622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Partnership and outcomes in men with prostate cancer.
    Bergman J; Gore JL; Saigal CS; Kwan L; Litwin MS
    Cancer; 2009 Oct; 115(20):4688-94. PubMed ID: 19626653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
    Konety BR; Cowan JE; Carroll PR;
    J Urol; 2008 May; 179(5):1797-803; discussion 1803. PubMed ID: 18343440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
    Schroeck FR; Sun L; Freedland SJ; Albala DM; Mouraviev V; Polascik TJ; Moul JW
    BJU Int; 2008 Jul; 102(1):28-32. PubMed ID: 18384634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy.
    Link BA; Nelson R; Josephson DY; Yoshida JS; Crocitto LE; Kawachi MH; Wilson TG
    J Urol; 2008 Sep; 180(3):928-32. PubMed ID: 18635217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of social networks and partnership status on treatment choice in men with localized prostate cancer.
    Chamie K; Kwan L; Connor SE; Zavala M; Labo J; Litwin MS
    BJU Int; 2012 Apr; 109(7):1006-12. PubMed ID: 21895934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.